FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2753476375> ?p ?o ?g. }

• W2753476375 abstract "Objectives The nucleoside reverse transcriptase inhibitors (NRTI) have been an important 'back-bone' of an antiretroviral therapy (ART) for HIV-1 infected patients. However, these agents have been associated with both short and long-term toxicity. Therefore, there has been growing interest in evaluating NRTI-sparing regimens. Now we have administered dolutegravir (DTG) and rilpivirine (RPV) to HIV-1 infected patients as a new NRTI-sparing regimen. However, there are few data on the outcome of ART regimen consisting of DTG and RPV. In this study, we examined treatment outcome for this NRTI-sparing regimen in HIV-1 infected patients. Method We examined 27 HIV-1 infected patients treated with NRTI-sparing regimen consisting of DTG and RPV in Nagoya Medical Center, Japan. We checked efficacy and safety for this regimen from 2014 to 2015, retrospectively. Results Median duration of this NRTI-sparing regimen for 27 Japanese HIV-1 infected patients (26 males, 1 female; mean age 57 years) was 323 days. The reasons for changing to this regimen were pill burden (n=13), lipodystrophy related to NRTI (n=7), myelopathy (n=2), renal dysfunction (n=1), dyslipidemia (n=1), respectively. Finally, 25 patients have continued this regimen. After starting this regimen, HIV viral load were soon less than the detection limit for all patients. Virologic failure and regimen discontinuations by severe adverse reactions were not confirmed for individuals. In addition, abnormal laboratory data (ALT, AST, etc) were not shown for all patients. Conclusions Current UK and US treatment guidelines do not recommend NRTI-sparing regimens for people starting ART due to concerns about toxicity, treatment discontinuation, and drug resistance. In this study, 12 patients had been already treated with NRTI-sparing regimen (Raltegravir + RPV). As these patients were elder, it was essential to reduce pill burden. Therefore, a new NRTI-sparing regimen, DTG + RPV, will be available in the future because of reducing pill burden, few drug interactions and low toxicity." @default.
• W2753476375 created "2017-09-15" @default.
• W2753476375 creator A5002554925 @default.
• W2753476375 creator A5023361838 @default.
• W2753476375 creator A5028963779 @default.
• W2753476375 creator A5064091238 @default.
• W2753476375 creator A5070603339 @default.
• W2753476375 creator A5085854031 @default.
• W2753476375 creator A5088610121 @default.
• W2753476375 date "2017-09-07" @default.
• W2753476375 modified "2023-09-27" @default.
• W2753476375 title "Treatment outcome for NRTI-sparing regimen consisting of dolutegravir and rilpivirine in HIV-1 infected patients" @default.
• W2753476375 doi "https://doi.org/10.1016/j.nhccr.2017.06.175" @default.
• W2753476375 hasPublicationYear "2017" @default.
• W2753476375 type Work @default.
• W2753476375 sameAs 2753476375 @default.
• W2753476375 citedByCount "0" @default.
• W2753476375 crossrefType "journal-article" @default.
• W2753476375 hasAuthorship W2753476375A5002554925 @default.
• W2753476375 hasAuthorship W2753476375A5023361838 @default.
• W2753476375 hasAuthorship W2753476375A5028963779 @default.
• W2753476375 hasAuthorship W2753476375A5064091238 @default.
• W2753476375 hasAuthorship W2753476375A5070603339 @default.
• W2753476375 hasAuthorship W2753476375A5085854031 @default.
• W2753476375 hasAuthorship W2753476375A5088610121 @default.
• W2753476375 hasBestOaLocation W27534763751 @default.
• W2753476375 hasConcept C126322002 @default.
• W2753476375 hasConcept C142462285 @default.
• W2753476375 hasConcept C159047783 @default.
• W2753476375 hasConcept C197934379 @default.
• W2753476375 hasConcept C2778723075 @default.
• W2753476375 hasConcept C2779502633 @default.
• W2753476375 hasConcept C2781413609 @default.
• W2753476375 hasConcept C2993143319 @default.
• W2753476375 hasConcept C3013748606 @default.
• W2753476375 hasConcept C71924100 @default.
• W2753476375 hasConceptScore W2753476375C126322002 @default.
• W2753476375 hasConceptScore W2753476375C142462285 @default.
• W2753476375 hasConceptScore W2753476375C159047783 @default.
• W2753476375 hasConceptScore W2753476375C197934379 @default.
• W2753476375 hasConceptScore W2753476375C2778723075 @default.
• W2753476375 hasConceptScore W2753476375C2779502633 @default.
• W2753476375 hasConceptScore W2753476375C2781413609 @default.
• W2753476375 hasConceptScore W2753476375C2993143319 @default.
• W2753476375 hasConceptScore W2753476375C3013748606 @default.
• W2753476375 hasConceptScore W2753476375C71924100 @default.
• W2753476375 hasLocation W27534763751 @default.
• W2753476375 hasOpenAccess W2753476375 @default.
• W2753476375 hasPrimaryLocation W27534763751 @default.
• W2753476375 hasRelatedWork W1488699347 @default.
• W2753476375 hasRelatedWork W1985140035 @default.
• W2753476375 hasRelatedWork W1985646480 @default.
• W2753476375 hasRelatedWork W2032393653 @default.
• W2753476375 hasRelatedWork W2074836524 @default.
• W2753476375 hasRelatedWork W2094799735 @default.
• W2753476375 hasRelatedWork W2156627312 @default.
• W2753476375 hasRelatedWork W2161944574 @default.
• W2753476375 hasRelatedWork W2303313041 @default.
• W2753476375 hasRelatedWork W2509806891 @default.
• W2753476375 hasRelatedWork W2611800914 @default.
• W2753476375 hasRelatedWork W2892666826 @default.
• W2753476375 hasRelatedWork W2898888794 @default.
• W2753476375 hasRelatedWork W2911705680 @default.
• W2753476375 hasRelatedWork W2935870568 @default.
• W2753476375 hasRelatedWork W2953641579 @default.
• W2753476375 hasRelatedWork W3026202394 @default.
• W2753476375 hasRelatedWork W3091898825 @default.
• W2753476375 hasRelatedWork W3182391226 @default.
• W2753476375 hasRelatedWork W48464209 @default.
• W2753476375 isParatext "false" @default.
• W2753476375 isRetracted "false" @default.
• W2753476375 magId "2753476375" @default.
• W2753476375 workType "article" @default.